RxDoctor Payments Data

Divya Gupta, MD

Internal Medicine · Houston, TXNPI 1205099256

Payments from drug & device makers

$1,020in general payments, 2019–2025

Across 11 payments — averaging $92.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aadi Bioscience, Inc.$848
  • Novo Nordisk$50
  • Hologic Sales And Service, LLC$43
  • Abbott$29
  • Lilly USA, LLC$24
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$14
  • plus $12 from 1 others

What the payments were for

  • Travel & lodging$84883%
  • Food & beverage$17317%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,020 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$73,932
Medicare patients
247
Services billed
835

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$84,625
JanuviaSitagliptin Phosphate35$51,844
JardianceEmpagliflozin23$38,671
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$11,810
Atorvastatin Calcium428$3,768
Levothyroxine Sodium324$3,645
Amlodipine Besylate339$2,335
SynthroidLevothyroxine Sodium29$2,306
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,078
Rosuvastatin Calcium147$1,812
Metformin Hcl185$1,722
Metoprolol Succinate110$1,644
Gabapentin76$1,643
Lisinopril188$1,635
Losartan Potassium185$1,425

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$50$84,62549 claims
MerckJanuvia$12$51,84435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →